---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-020677"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:36:59.685727+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lipocine presents LPCN 2401 Phase 2 data at ObesityWeek showing improved body composition and liver health

## Summary
- In Phase 2 trial, LPCN 2401 increased lean mass, reduced fat mass, and improved fat-to-lean ratio vs placebo at 20 and 36 weeks.
- Treatment with LPCN 2401 showed rapid reductions in liver fat content and liver injury markers (ALT, AST) starting at 4-8 weeks.
- MRI-PDFF demonstrated significant reductions in liver fat at 12 weeks, maintained through week 36.
- LPCN 2401 was well tolerated with no concerning safety signals observed through 72 weeks of exposure.

## SEC filing metadata
- accession: 0001493152-25-020677
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225020677/0001493152-25-020677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225020677/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-020677
- JSON: https://secwatch.observer/filing/0001493152-25-020677.json
- Plain text: https://secwatch.observer/filing/0001493152-25-020677.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.